Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?

Arcutis Biotherapeutics (ARQT) has significantly outperformed the broader Medical sector year-to-date, posting a 26.1% return against the sector's -3.1% average. This strong performance is underpinned by a Zacks Rank of #2 (Buy) and a 20.9% increase in its full-year earnings consensus estimate over the past quarter, signaling improving analyst sentiment. Cardinal Health (CAH) also stands out with a 30% YTD return and a #2 (Buy) Zacks Rank, indicating these stocks are notable outperformers within a generally lagging sector.

Analysis

Arcutis Biotherapeutics (ARQT) is demonstrating significant fundamental and market strength, contrasting sharply with the broader Medical sector's underperformance. Year-to-date, ARQT has delivered a 26.1% return, substantially outpacing the Medical sector's average loss of 3.1% and its specific Medical - Biomedical and Genetics industry's gain of 2.4%. The key driver behind this outperformance appears to be a notable improvement in its earnings outlook, evidenced by a 20.9% increase in the Zacks Consensus Estimate for its full-year earnings over the last quarter. This positive revision has earned the stock a Zacks Rank of #2 (Buy), which the methodology suggests is a predictor of market outperformance over the next one to three months. The article also highlights Cardinal Health (CAH) as another strong performer within the Medical sector, which posted a 30% year-to-date return and also holds a #2 (Buy) rank, supported by a 2.2% increase in its consensus EPS estimate. The performance of both ARQT and CAH indicates that despite overall sector weakness, specific companies with improving analyst sentiment and strong earnings estimate revisions are managing to capture investor interest and generate alpha.

Key Decisions for Investors

• Given the significant 20.9% upward revision in full-year earnings estimates and a Zacks Rank of #2 (Buy), investors may consider Arcutis Biotherapeutics a candidate for near-term momentum strategies, as these factors are presented as indicators of potential outperformance.
• The stark divergence between the performance of ARQT (+26.1%) and the broader Medical sector (-3.1%) underscores the importance of a stock-specific selection approach over a passive sector allocation in the current environment.
• Investors should monitor for continued positive earnings estimate revisions for both Arcutis Biotherapeutics and Cardinal Health, as the bullish thesis presented is heavily dependent on the continuation of this trend according to the cited Zacks Rank methodology.